In the Philippines, there is limited public funding of healthcare and patients often have to pay out of their own pocket for treatment. Around 20% of the population have medical insurance plans through their employer; the other 80% have to pay out of pocket. The government-owned Philippine Healthcare Insurance Corporation (PhilHealth) provides basic national healthcare coverage, however, it doesn’t include treatment with biologics.
The Roche Patient Access Program was established to help people who are financially constrained, through a socialised pricing program that considers the individual affordability level of a patient. Physicians refer patients to the program, who are then for assessed by an independent third party for their ability to pay. Qualified patients receive a discounted price for Herceptin based on their financial status. This differential pricing improves access to products for poorer patients without impacting the price for patients able to pay out of pocket.
In addition, Roche has established HER2 programs to create awareness of the need for HER2 testing and to improve testing accuracy.
As another way to improve healthcare coverage, Roche has partnered with Philam Life Insurance, Pru Life Insurance and five health management organisations to develop cancer insurance programs.
|Location||East Asia and Pacific, Philippines|